Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $2.3 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 44.15% year-over-year to $2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 43.98% YoY) and the FY2025 annual result came in at $1.4 billion, up 21.54% from the prior year.
• Liabilities and Shareholders Equity climbed to $2.3 billion in Q1 2026, from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q1 2026 to a low of $626.3 million in Q4 2023.
• A 5-year average of $1.1 billion and a median of $891.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity dropped 29.75% — and 2025, when it jumped 64.74%.
• Tracing ARWR's Liabilities and Shareholders Equity over 5 years: stood at $891.5 million in 2022, then retreated by 29.75% to $626.3 million in 2023, then soared by 61.86% to $1.0 billion in 2024, then soared by 58.25% to $1.6 billion in 2025, then jumped by 41.4% to $2.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.